TERF2

TERF2 (TRF2) is a telomeric double-strand DNA-binding protein that protects chromosome ends and governs the DNA damage response, with its DNA-binding domain required for proper targeting to telomeres (PMID:15878333). At chromosome ends, loss of TERF2 triggers telomere dysfunction that activates an ATM- and TP53-dependent, ATR-independent apoptotic program; in neural progenitors this drives catastrophic cell loss, and unrepaired double-strand breaks processed by NHEJ (Lig4) underlie the multinucleated cells that arise when p53 is absent (PMID:28620865). Beyond telomeres, TERF2 forms a complex with the nucleotide excision repair endonuclease XPF that acts at non-telomeric damage sites upstream of ATM signaling, such that TERF2 overexpression sensitizes cells to UV and crosslinking agents in an XPF-dependent manner (PMID:16762604). TERF2 also exerts a non-telomeric regulatory role by binding directly to HMGB1 and restricting its cytoplasmic translocation; this interaction suppresses autophagy, as TERF2 silencing drives HMGB1 to the cytosol and stimulates autophagy while a binding-deficient mutant fails to suppress it (PMID:36310382).

1. 2005 Medium

   Established that TERF2's telomeric localization is an intrinsic property of its DNA-binding domain, defining how the protein finds chromosome ends.

   Evidence TRF2-GFP fusion imaging and DNA-binding-domain deletion mutants in muntjac fibroblast cell lines

   PMID:15878333

   Open questions at the time

   • Single lab and single ortholog cell line
   • Does not address what stabilizes TERF2 once bound or which cofactors are required
   • No structural detail of the DNA-binding interface
2. 2006 Medium

   Extended TERF2 function beyond telomeres by showing it partners with XPF to act at non-telomeric DNA damage sites prior to ATM signaling.

   Evidence TERF2 overexpression in XPF-deficient vs. XPF-proficient cells with UV/crosslinker sensitivity assays, synthesized in a review commentary

   PMID:16762604

   Open questions at the time

   • Evidence summarized from original papers in a review context
   • Molecular nature of the TERF2-XPF complex and its substrate are not defined
   • Physiological relevance of the gain-of-function hypersensitivity is unclear
3. 2017 High

   Defined the genetic pathway of TERF2 loss in vivo, showing telomere dysfunction signals through ATM and TP53 (not ATR) to drive apoptosis and that NHEJ underlies aberrant cell formation.

   Evidence Conditional Terf2 knockout in mouse neural progenitors crossed with Atm, Atr, Trp53, and Lig4 knockouts, with developmental histology

   PMID:28620865

   Open questions at the time

   • Restricted to the neural progenitor context
   • Does not resolve the molecular step linking telomere deprotection to ATM activation
   • Role of TERF2 partners in this signaling is not addressed
4. 2022 High

   Uncovered a non-telomeric role for TERF2 as a direct binding partner that sequesters HMGB1 in the nucleus to restrain autophagy.

   Evidence Co-IP, PLA, wild-type vs. binding-deficient TERF2 mutant rescue, HMGB1 knockdown/inhibitor epistasis, and GFP-LC3 autophagy reporter

   PMID:36310382

   Open questions at the time

   • Whether HMGB1 binding occurs at telomeres or elsewhere is not localized
   • How TERF2's telomeric and autophagy-regulatory functions are coordinated is unknown
   • In vivo relevance of the autophagy axis is not established
5. 2024 Medium

   Positioned TERF2 within regulatory and oncogenic networks: as a target of miR-29b-1-5p in myocardial injury and, when fused to PDGFRB, as a driver of kinase-dependent proliferation.

   Evidence Dual luciferase 3'UTR validation with TERF2-knockdown rescue in cardiomyocytes; Ba/F3 expression of TERF2::PDGFRB fusion with STAT5 signaling readouts and imatinib sensitivity

   PMID:38323741 PMID:38414350

   Open questions at the time

   • miR-29b axis is correlative for endogenous TERF2 protein function
   • The fusion's oncogenic activity reflects PDGFRB kinase rather than native TERF2 function
   • Single-lab studies in defined model systems
6. 2024 Low

   Began to address how TERF2 is retained at telomeres in ALT cancer cells, implicating TOP3A activity in its stabilization.

   Evidence Telomere enrichment/ChIP comparing ALT vs. telomerase-positive cells with TOP3A depletion and DPC induction (preprint)

   PMID:bio_10.1101_2024.11.18.624152

   Open questions at the time

   • Preprint; lacks full mechanistic reconstitution
   • Mechanism by which TOP3A stabilizes TERF2 is undefined
   • Generalizability beyond the ALT cell context is untested
7. 2025 Low

   Correlated TERF2 telomere de-protection with disease, linking reduced telomeric TERF2 to telomere damage signaling in failing human hearts.

   Evidence Telomere ChIP, γH2AX/TIF assays, and overhang measurements in failing vs. non-failing human left ventricular tissue (preprint)

   PMID:bio_10.1101_2025.08.12.669993

   Open questions at the time

   • Preprint; observational and correlative without TERF2 manipulation
   • Causality between TERF2 loss and heart failure is not established
   • Mechanism of TERF2 loss from telomeres in failing hearts is unknown

• How TERF2 coordinates its telomere-protective DNA-binding role with its non-telomeric XPF and HMGB1 functions, and what governs its stability at telomeres in different cellular contexts, remains unresolved.
• No structural model integrating DNA binding with partner interactions
• Mechanism of TERF2 stabilization/loss at telomeres across cell types undefined
• Direct causal link between TERF2 de-protection and human disease not demonstrated